NovoCure Ltd
NVCR
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.91B
Close$
$-8.49
148.9% downside
Current Fair Value
148.9% downsideOvervalued by 148.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.91 Billion |
|---|---|
| Enterprise Value | $2.05 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.22 |
| Beta | 0.94 |
| Outstanding Shares | 116,012,397 |
Return
| Return on Equity | -43.94% |
|---|---|
| Return on Assets | -18.68% |
| Return on Invested Capital | -26.97% |
Valuation & Multiples
| P/E Ratio | -12.61 |
|---|---|
| PEG | 20.67 |
| Price to Sales | 2.9 |
| Price to Book Ratio | 8.69 |
| Enterprise Value to Revenue | 2.93 |
| Enterprise Value to EBIT | -13.22 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.69 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 23, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
$172.44 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.21
Average shareholder expectationRevenue Estimate
$182.28 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0355▼ 70.87% |
|---|---|
| Total Calls | 16,900▼ 98.18% |
| Total Puts | 600▼ 99.91% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 18.86%▼ 69.85% |
|---|---|
| Total Invested | $326.40M▼ 69.70% |
| Investors Holding | 80▼ 152.00% |
ESG Score
No data
About NovoCure Ltd
CEO: Asaf Danziger